21236 Herve Avet-Loiseau/.../Regis Bataille: 14q32 translocations and
monosomy 13 observed in monoclonal gammopathy of undetermined
significance delineate a multistep process for the oncogenesis of
multiple myeloma. Cancer Res. 59 (1999), 4546-4550.

21235 Herve Avet-Loiseau/.../Claire Mathiot: Genetic abnormalities and
survival in multiple myeloma - the experience of the Intergroupe
Francophone du Myelome. Bllod 109/8 (2007), 3489-3495.

21250 Herve Avet-Loiseau/.../Stephane Minvielle: Prognostic significance
of copy-number alterations in multiple myeloma.
J. Clin. Onc. ... (2009), 7p.

21243 P. Leif Bergsagel/W. Kuehl: Molecular pathogenesis and a consequent
classification of multiple myeloma. J. Clin. Onc. 23/26 (2006), 6333-6338.

21470 Daniel Carrasco/.../Ronald De Pinho: High resolution genomic
profiles define distincto clinico-pathogenetic subgroups of multiple
myeloma patients. Cancer Cell 9 (2006), 313-325.

21242 Wee Chng/.../Rafael Fonseca: Molecular dissection of hyperdiploid
multiple myeloma by gene expression profiling.
Cancer Res. 67/7 (2007), 2982-2989.

21244 Rafael Fonseca/.../Herve Avet-Loiseau: Genetics and cytogenetics
of multiple myeloma - a workshop report. Cancer Res. 64 (2004), 1546-1558.

21245 Ana Gabrea/P. Leif Bergsagel/W. Kuehl: Distinguishing primary and
secondary translocations in multiple myeloma. DNA Repair 5 (2006), 1225-1233.

21569 Sandra Grass/.../Michael Pfreundschuh: Association of a
dominantly inherited hyperphosphorylated paraprotein target with
sporadic and familial multiple myeloma and monoclonal gammopathy
of undetermined significance - a case-control study.
Lancet Oncology 10 (2009), 950-956.

21575 H. Hosgood/.../Qing Lan: Genetic variation in cell cycle
and apoptosis related genes and multiple myeloma risk.
Leukemia Res. 33 (2009), 1609-1614.

21239 Prashant Kapoor/.../S. Rajkumar: Impact of risk stratification on
outcome among patients with multiple myeloma receiving initial therapy
with lenalidomide and dexamethasone. Blood 114/3 (2009), 518-521.

21241 Jonathan Keats/.../P. Leif Bergsagel: Promiscuous mutations activate
the noncanonical NF-kB pathway in multiple myeloma.
Cancer Cell 12 (2007), 131-144.

21286 Flavia Pichiorri/.../Stefano Volinia/.../Carlo Croce: MicroRNAa
regulate critical genes associated with multiple myeloma pathogenesis.
Proc. Nat. Ac. Sci. USA 105/35 (2008), 12885-12890.

21237 Jeffrey Sawyer/James Waldron/Sundar Jagannath/Bart Barlogie:
Cytogenetic findings in 200 patients with multiple myeloma.
Cancer Gen. Cytogen. 82 (1995), 41-49.

21247 Nicole Smadja/.../Christian Bastard: Chromosomal analysis in multiple
myeloma - cytogenetic evidence of two different diseases.
Leukemia 12 (1998), 960-969.

21246 Nicole Smadja/.../Christophe Fruchart: Hypodiploidy is a major
prognostic factor in multiple myeloma. Bllod 98/7 (2001), 2229-2238.

21200 Brian Van Ness/.../Gareth Morgan: Genomic variation in myeloma -
design, content, and initial application of the Bank On A Cure SNP Panel
to detect associations with progression-free survival.
BMC Med. 6/26 (2008), 14p.

21211 Brian Van Ness: Techniques for studying genetic technologies.
IWMF Bull. September 2009, 8-10.

21570 ZZ: Erstmals dominant vererbte Veranlagung entdeckt.
Internet 2009, 1p. Zusammenfassung von 21569 Grass/.